283 related articles for article (PubMed ID: 16387861)
41. Improvement of calcium handling and changes in calcium-release properties after mini- or full-length dystrophin forced expression in cultured skeletal myotubes.
Marchand E; Constantin B; Balghi H; Claudepierre MC; Cantereau A; Magaud C; Mouzou A; Raymond G; Braun S; Cognard C
Exp Cell Res; 2004 Jul; 297(2):363-79. PubMed ID: 15212940
[TBL] [Abstract][Full Text] [Related]
42. Site-specific genomic integration produces therapeutic Factor IX levels in mice.
Olivares EC; Hollis RP; Chalberg TW; Meuse L; Kay MA; Calos MP
Nat Biotechnol; 2002 Nov; 20(11):1124-8. PubMed ID: 12379870
[TBL] [Abstract][Full Text] [Related]
43. Gene therapy for muscular disease.
Johnston N
Drug Discov Today; 2004 Sep; 9(18):777. PubMed ID: 15364061
[No Abstract] [Full Text] [Related]
44. Functional efficacy of dystrophin expression from plasmids delivered to mdx mice by hydrodynamic limb vein injection.
Zhang G; Wooddell CI; Hegge JO; Griffin JB; Huss T; Braun S; Wolff JA
Hum Gene Ther; 2010 Feb; 21(2):221-37. PubMed ID: 19788386
[TBL] [Abstract][Full Text] [Related]
45. [Gene hACR-1 suppresses apoptosis of striated muscle fibres of m. quadriceps femoris after ballistic transfection of mdx mice].
Mikhaĭlov VM; Kropotov AV; Tomilin NV; Zelenin AV; Krutilina RI; Kolesnikov VA; Ostapenko OV; Zelenina IA; Baranov AN; Shteĭn GI; Baranov VS
Tsitologiia; 2002; 44(4):374-8. PubMed ID: 12149782
[TBL] [Abstract][Full Text] [Related]
46. Naked plasmid DNA for the treatment of muscular dystrophy.
Braun S
Curr Opin Mol Ther; 2004 Oct; 6(5):499-505. PubMed ID: 15537051
[TBL] [Abstract][Full Text] [Related]
47. Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice.
Ito K; Kimura S; Ozasa S; Matsukura M; Ikezawa M; Yoshioka K; Ueno H; Suzuki M; Araki K; Yamamura K; Miwa T; Dickson G; Thomas GD; Miike T
Hum Mol Genet; 2006 Jul; 15(14):2266-75. PubMed ID: 16777842
[TBL] [Abstract][Full Text] [Related]
48. [Molecular therapy of muscular dystrophy].
Takeda S
Rinsho Shinkeigaku; 2000 Dec; 40(12):1267-9. PubMed ID: 11464475
[TBL] [Abstract][Full Text] [Related]
49. [Construction of recombinant plasmid pVAX1-microdystrophin and preliminary study on the treatment to Duchenne muscular dystrophy].
Xiong F; Zhang C; Zheng H; Xiao S; Yu M; Xu Y; Liu Z; Zhou C
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):624-8. PubMed ID: 19065517
[TBL] [Abstract][Full Text] [Related]
50. RNAi-mediated knockdown of dystrophin expression in adult mice does not lead to overt muscular dystrophy pathology.
Ghahramani Seno MM; Graham IR; Athanasopoulos T; Trollet C; Pohlschmidt M; Crompton MR; Dickson G
Hum Mol Genet; 2008 Sep; 17(17):2622-32. PubMed ID: 18511456
[TBL] [Abstract][Full Text] [Related]
51. [Suppression of nonsense mutations in the Dystrophin gene by a suppressor tRNA gene].
Kiselev AV; Ostapenko OV; Rogozhkina EV; Kholod NS; Seit Nebi AS; Baranov AN; Lesina EA; Ivashchenko TE; Sabetskiĭ VA; Shavlovskiĭ MM; Rechinskiĭ VO; Kiselev LL; Baranov VC
Mol Biol (Mosk); 2002; 36(1):43-7. PubMed ID: 11862712
[TBL] [Abstract][Full Text] [Related]
52. Dystrophin and muscular dystrophy: past, present, and future.
O'Brien KF; Kunkel LM
Mol Genet Metab; 2001; 74(1-2):75-88. PubMed ID: 11592805
[TBL] [Abstract][Full Text] [Related]
53. A direct comparison of two nonviral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage integrase phiC31 and the Sleeping Beauty transposase.
Ehrhardt A; Xu H; Huang Z; Engler JA; Kay MA
Mol Ther; 2005 May; 11(5):695-706. PubMed ID: 15851008
[TBL] [Abstract][Full Text] [Related]
54. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer.
Wu B; Moulton HM; Iversen PL; Jiang J; Li J; Li J; Spurney CF; Sali A; Guerron AD; Nagaraju K; Doran T; Lu P; Xiao X; Lu QL
Proc Natl Acad Sci U S A; 2008 Sep; 105(39):14814-9. PubMed ID: 18806224
[TBL] [Abstract][Full Text] [Related]
55. Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEI copolymers.
Williams JH; Sirsi SR; Latta DR; Lutz GJ
Mol Ther; 2006 Jul; 14(1):88-96. PubMed ID: 16488666
[TBL] [Abstract][Full Text] [Related]
56. Site-specific integration with phiC31 integrase for prolonged expression of therapeutic genes.
Ginsburg DS; Calos MP
Adv Genet; 2005; 54():179-87. PubMed ID: 16096012
[TBL] [Abstract][Full Text] [Related]
57. Intraarterial delivery of naked plasmid DNA expressing full-length mouse dystrophin in the mdx mouse model of duchenne muscular dystrophy.
Zhang G; Ludtke JJ; Thioudellet C; Kleinpeter P; Antoniou M; Herweijer H; Braun S; Wolff JA
Hum Gene Ther; 2004 Aug; 15(8):770-82. PubMed ID: 15319034
[TBL] [Abstract][Full Text] [Related]
58. Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase -- increased expression with reduced muscle damage.
McMahon JM; Signori E; Wells KE; Fazio VM; Wells DJ
Gene Ther; 2001 Aug; 8(16):1264-70. PubMed ID: 11509960
[TBL] [Abstract][Full Text] [Related]
59. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
[TBL] [Abstract][Full Text] [Related]
60. Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy.
Duan D
Curr Opin Mol Ther; 2008 Feb; 10(1):86-94. PubMed ID: 18228186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
